510(k) for PharmaNetics' thrombolytic assessment system supplements
This article was originally published in Clinica
The US FDA has cleared PharmaNetics' electronic quality control test card and software upgrade for its thrombolytic assessment system (TAS). The reusable test card gives a three-level check to the TAS analyser as well as enhances the self-checks performed when the machine is initially switched on. According to the Raleigh, North Carolina-based company, the TAS software expands the menu of tests processed by the analyser and allows it to be linked to PharmaNetic's new Accent product which is currently awaiting FDA clearance.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.